Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 19.7% – What’s Next?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN)’s stock price traded down 19.7% during trading on Tuesday . The company traded as low as $0.9701 and last traded at $0.9955. 270,882 shares changed hands during mid-day trading, a decline of 74% from the average session volume of 1,029,491 shares. The stock had previously closed at $1.24.

Qualigen Therapeutics Trading Down 19.7%

The stock has a market capitalization of $1.69 million, a PE ratio of -0.13 and a beta of 0.24. The business’s 50 day moving average is $2.09 and its 200 day moving average is $2.63.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.